KORU Medical Systems, Inc. (KRMD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 12, 2025, announces the financial results for the fourth quarter and full year ended December 31, 2024. The filing also includes financial guidance for the fiscal year ending December 31, 2025. A related conference call was scheduled for March 12, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report references a press release (Exhibit 99.1) containing these details. The Company utilizes non-GAAP measures, specifically Adjusted EBITDA and Adjusted EPS, to supplement GAAP results. Adjusted EBITDA excludes interest, taxes, depreciation, amortization, reorganization charges, discontinued product expenses, litigation expenses, manufacturing initiative expenses, and stock-based compensation. Adjusted EPS similarly excludes these items to reflect underlying operating results.
Material Changes
The filing text does not disclose specific material changes in financial performance compared to prior periods. Investors are directed to the attached press release for a reconciliation of GAAP to non-GAAP results and detailed performance comparisons.
Guidance, Outlook, and Risks
The Company issued financial guidance for the fiscal year 2025. Management emphasizes that non-GAAP measures should not replace GAAP measures and may differ from similar measures used by other companies. The filing includes standard cautionary language regarding the use of non-GAAP financial measures and notes that the information in Item 2.02 is not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2024 revenue, net income, and cash flow figures.
- Examine the reconciliation of GAAP to non-GAAP Adjusted EBITDA and Adjusted EPS to understand the magnitude of excluded items.
- Verify the specific numerical targets provided in the 2025 fiscal year guidance.
- Assess the impact of reorganization charges, litigation expenses, and discontinued product expenses on reported results.